NCT07134218尚未招募2 期
A National Multicenter, Prospective, Randomized Controlled Study of Serplulimab Injection Combined With Bevacizumab to Improve the Complete Response Rate of Neoadjuvant Therapy for Locally Advanced Stage Intermediate and Low Rectal Cancer
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- The rate of cCR
研究概览
简要总结
This is a multicenter, prospective, randomized phase II trial designed to evaluate the efficacy and safety of short-course neoadjuvant chemoradiotherapy combined with the PD-1 monoclonal antibody serplulimab and the anti-angiogenic agent bevacizumab in patients with previously untreated pMMR/MSS middle and low locally advanced rectal cancer. The study plans to enroll a total of 200 participants (100 in the experimental arm and 100 in the control arm).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent to voluntarily participate in the study;
- •Aged 18 to 75 years, inclusive, regardless of sex;
- •Histologically confirmed rectal adenocarcinoma with immunohistochemistry results showing proficient mismatch repair (pMMR) or molecular testing results indicating microsatellite stability (MSS);
- •Clinical baseline staging assessed by MRI as T3-4N0M0/TanyN+M, with negative mesorectal fascia (MRF);
- •Tumor lower margin ≤7 cm from the anal verge;
- •Surgically resectable;
- •Capable of swallowing tablets normally;
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1;
- •No prior anti-tumor treatment for rectal cancer, including radiotherapy, chemotherapy, or surgery;
- •Planned to undergo surgical treatment after completion of neoadjuvant therapy;
- •No contraindications to surgery;
- •Normal function of major organs.
排除标准
- •History of allergy to any component of bevacizumab, serplulimab, 5-FU, or oxaliplatin.
- •Prior or ongoing treatment with any of the following:
- •Any tumor-targeted surgery, radiotherapy, chemotherapy, targeted therapy, or immunotherapy.
- •Immunosuppressive drugs or systemic corticosteroid therapy for immunosuppressive purposes within 2 weeks before the first administration of the study drug (dose > 10 mg/day prednisone or equivalent). Inhaled or topical corticosteroids and adrenal corticosteroid replacement therapy (dose > 10 mg/day prednisone or equivalent) are permitted in the absence of active autoimmune disease.
- •Live-attenuated vaccine within 4 weeks before the first administration of the study drug.
- •Major surgery or severe trauma within 4 weeks before the first administration of the study drug.
- •Presence of any active autoimmune disease or history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (participants on hormone replacement therapy may be considered for inclusion). Participants with psoriasis or childhood asthma/allergy that has fully resolved and requires no intervention in adulthood may be considered for inclusion, but those requiring bronchodilator therapy are not eligible.
- •History of immunodeficiency, including HIV positivity, or other acquired or congenital immunodeficiency diseases, or history of organ transplant or allogeneic bone marrow transplant.
- •Uncontrolled cardiac symptoms or diseases, including but not limited to: (1) NYHA class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within the past year, (4) clinically significant supraventricular or ventricular arrhythmias that are not controlled or remain poorly controlled after clinical intervention.
- •Severe infection (CTCAE > grade 2) within 4 weeks before the first administration of the study drug, such as severe pneumonia, bacteremia, or infection with complications requiring hospitalization. Baseline chest imaging showing active pulmonary inflammation, or presence of signs and symptoms of infection or need for oral or intravenous antibiotic therapy within 14 days before the first administration of the study drug (excluding prophylactic antibiotic use). History of active pulmonary tuberculosis infection identified through medical history or CT scan, or history of active pulmonary tuberculosis infection within the past year, or history of active pulmonary tuberculosis infection more than 1 year ago that was not properly treated.
- •Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10⁴ copies/mL), hepatitis C (positive HCV antibody and HCV RNA above the lower limit of detection of the assay).
- •Diagnosis of other malignancies within 5 years before the first administration of the study drug, unless the malignancy has a low risk of metastasis or death (5-year survival rate > 90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ, which may be considered for inclusion.
- •Pregnant or breastfeeding women.
- •Presence of other factors that, in the investigator's judgment, may lead to forced discontinuation of the study, such as other severe diseases (including psychiatric conditions) requiring concomitant treatment, alcoholism, drug abuse, family or social factors that may affect the participant's safety or compliance.
研究组 & 干预措施
neoadjuvant chemoradiation therapy + serplulimab + bevacizumab
Experimental
干预措施: serplulimab、bevacizumab (Drug)
neoadjuvant chemoradiation therapy
Other
干预措施: serplulimab、bevacizumab (Drug)
neoadjuvant chemoradiation therapy
Other
干预措施: neoadjuvant chemoradiation therapy (Other)
结局指标
主要结局
The rate of cCR
时间窗: 2 years
Rate of patients who achieve clinical complete response
次要结局
- Organ Preservation Rate (OPR)(2 years)
- Neoadjuvant Rectal Score (NAR)(2 years)
- Safety and Tolerability(2 years)
- Major Pathological Response(2 years)
- Objective Response Rate(2 years)
- Disease-Free Survival (DFS)(2 years)
- Overall Survival (OS)(2 years)
- Quality of Life Score (QoL)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Clinical Study to Evaluate the Effectiveness and Safety of NTC chondrograft® versus the Standard Procedure Arthroscopic Microfracture as the Standard Procedure in the Treatment of Symptomatic Articular Cartilage Defects of the KneeSymptomatic knee articular cartilage defectsEUCTR2017-002601-35-CZPrimeCell Advanced Therapy a.s.214
尚未招募
Unknown
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Effectiveness of REAL INTELLIGENCE™ CORI™ in unicondylar knee arthroplasty (UKA) ProcedureKCT0008693Smith & Nephew30
尚未招募
Unknown
A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in total knee arthroplasty (TKA) ProcedureDiseases of the musculoskeletal system and connective tissueKCT0008692Smith & Nephew40
已完成
不适用
A Multicenter, Prospective, Randomized Controlled Trial: SMC-01: A Mobile Medical Application to Improve Self-Management of Patients with Type 2 DiabetesType 2 DiabetesjRCT2032200033Save Medical Corporation200
已完成
3 期
A Multicenter, Prospective, Randomized Controlled Trial: SMC-01: A Mobile Medical Application to Improve Self-Management of Patients with Type 2 DiabetesD003924Type 2 DiabetesJPRN-jRCT2032200033Ohnishi Yukiko200